Perrigo said that it won a patent challenge for Famotidine Complete, the national brand equivalent to Pepcid Complete marketed by Johnson & Johnson – Merck Consumer Pharmaceuticals.
The new store brand product is indicated for heartburn associated with acid indigestion and sour stomach.
Joseph Papa, Perrigo’s president and CEO, stated: “This is another example of Perrigo’s investment in new products making quality healthcare more affordable to American consumers. Famotidine Complete is an important new store brand product in the gastrointestinal segment for our retail and wholesale customers and enables them to provide significant savings for the consumer.
“This is an important addition to our portfolio of products that saves the consumer of over-the-counter healthcare products approximately $1 billion annually when compared to the higher priced national brands.”